A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

OBJECTIVE: To demonstrate pharmacokinetic (PK) similarity of biosimilar candidate ABP 501 relative to adalimumab reference product from the USA and European Union (EU) and evaluate safety, tolerability and immunogenicity of ABP 501. METHODS: Randomised, single-blind, single-dose, three-arm, parallel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Rheum Dis
Egile Nagusiak: Kaur, Primal, Chow, Vincent, Zhang, Nan, Moxness, Michael, Kaliyaperumal, Arunan, Markus, Richard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2017
Gaiak:
Clinical and Epidemiological Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445997/
https://ncbi.nlm.nih.gov/pubmed/27466231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-208914
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak